CN103784397B - 葛根素磷酸酯钠注射液及其制备方法 - Google Patents
葛根素磷酸酯钠注射液及其制备方法 Download PDFInfo
- Publication number
- CN103784397B CN103784397B CN201310730090.5A CN201310730090A CN103784397B CN 103784397 B CN103784397 B CN 103784397B CN 201310730090 A CN201310730090 A CN 201310730090A CN 103784397 B CN103784397 B CN 103784397B
- Authority
- CN
- China
- Prior art keywords
- injection
- sodium phosphate
- puerarin
- preparation
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002347 injection Methods 0.000 title claims abstract description 165
- 239000007924 injection Substances 0.000 title claims abstract description 165
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 title claims abstract description 81
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 title claims abstract description 80
- 239000001488 sodium phosphate Substances 0.000 title claims abstract description 71
- 229910000162 sodium phosphate Inorganic materials 0.000 title claims abstract description 71
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 title claims abstract description 70
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 239000008215 water for injection Substances 0.000 claims abstract description 13
- 238000001914 filtration Methods 0.000 claims abstract description 12
- 238000005516 engineering process Methods 0.000 claims abstract description 11
- 239000002510 pyrogen Substances 0.000 claims abstract description 11
- 230000036592 analgesia Effects 0.000 claims abstract description 6
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 6
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 6
- 235000011008 sodium phosphates Nutrition 0.000 claims description 68
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 45
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 15
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 14
- 235000010265 sodium sulphite Nutrition 0.000 claims description 11
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 10
- 238000005261 decarburization Methods 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 238000013019 agitation Methods 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 229960004926 chlorobutanol Drugs 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 4
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 4
- 235000019800 disodium phosphate Nutrition 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 4
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 3
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 3
- -1 pH value regulator Substances 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 208000029078 coronary artery disease Diseases 0.000 abstract description 2
- 238000001179 sorption measurement Methods 0.000 abstract description 2
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 abstract 1
- 230000002421 anti-septic effect Effects 0.000 abstract 1
- 210000001367 artery Anatomy 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 238000005303 weighing Methods 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 154
- 206010018910 Haemolysis Diseases 0.000 description 45
- 230000007794 irritation Effects 0.000 description 45
- 210000004204 blood vessel Anatomy 0.000 description 40
- 230000008588 hemolysis Effects 0.000 description 40
- 238000012360 testing method Methods 0.000 description 40
- 241000283973 Oryctolagus cuniculus Species 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 31
- 210000003205 muscle Anatomy 0.000 description 30
- 210000001519 tissue Anatomy 0.000 description 30
- 210000003462 vein Anatomy 0.000 description 25
- 239000007788 liquid Substances 0.000 description 23
- 206010002198 Anaphylactic reaction Diseases 0.000 description 20
- 241000700199 Cavia porcellus Species 0.000 description 20
- 206010030113 Oedema Diseases 0.000 description 20
- 230000036783 anaphylactic response Effects 0.000 description 20
- 208000003455 anaphylaxis Diseases 0.000 description 20
- 238000000338 in vitro Methods 0.000 description 20
- 206010020565 Hyperaemia Diseases 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 15
- 230000004520 agglutination Effects 0.000 description 15
- 238000010790 dilution Methods 0.000 description 15
- 239000012895 dilution Substances 0.000 description 15
- 210000003743 erythrocyte Anatomy 0.000 description 15
- 239000002085 irritant Substances 0.000 description 11
- 231100000021 irritant Toxicity 0.000 description 11
- 206010015719 Exsanguination Diseases 0.000 description 10
- 210000005069 ears Anatomy 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 230000003203 everyday effect Effects 0.000 description 10
- 230000036285 pathological change Effects 0.000 description 10
- 231100000915 pathological change Toxicity 0.000 description 10
- 230000001575 pathological effect Effects 0.000 description 10
- 210000003314 quadriceps muscle Anatomy 0.000 description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 230000008859 change Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 240000006409 Acacia auriculiformis Species 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010028851 Necrosis Diseases 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000000172 allergic effect Effects 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 230000002146 bilateral effect Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 229940121657 clinical drug Drugs 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000003511 endothelial effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229940093181 glucose injection Drugs 0.000 description 5
- 230000002949 hemolytic effect Effects 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 238000010255 intramuscular injection Methods 0.000 description 5
- 239000007927 intramuscular injection Substances 0.000 description 5
- 230000000622 irritating effect Effects 0.000 description 5
- 239000002932 luster Substances 0.000 description 5
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 5
- 230000003387 muscular Effects 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 230000008520 organization Effects 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 239000013049 sediment Substances 0.000 description 5
- 230000008313 sensitization Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000219781 Pueraria montana var. lobata Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310730090.5A CN103784397B (zh) | 2013-12-26 | 2013-12-26 | 葛根素磷酸酯钠注射液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310730090.5A CN103784397B (zh) | 2013-12-26 | 2013-12-26 | 葛根素磷酸酯钠注射液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103784397A CN103784397A (zh) | 2014-05-14 |
CN103784397B true CN103784397B (zh) | 2016-01-20 |
Family
ID=50660741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310730090.5A Active CN103784397B (zh) | 2013-12-26 | 2013-12-26 | 葛根素磷酸酯钠注射液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103784397B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104013615A (zh) * | 2014-05-28 | 2014-09-03 | 西北农林科技大学 | 维生素c在葛根素注射剂中的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101712676B (zh) * | 2008-10-06 | 2013-02-13 | 深圳市健元医药科技有限公司 | 水溶性葛根素衍生物及其制备方法与用途 |
-
2013
- 2013-12-26 CN CN201310730090.5A patent/CN103784397B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN103784397A (zh) | 2014-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102144965A (zh) | 一种更加稳定的醋酸卡贝缩宫素注射剂 | |
CN102166186A (zh) | 一种更加稳定的氮杂环己肽类制剂 | |
CN102160852A (zh) | 一种布洛芬注射液及制备方法 | |
CN112426405A (zh) | 预防及控制近视发展的药物组合物、滴眼液及其制备方法与应用 | |
CN104688672B (zh) | 葛根素凝胶滴眼液在制备治疗眼底缺血性疾病药物中的应用 | |
CN102145164B (zh) | 一种更加稳定的iapp类似物注射剂 | |
CN102512379B (zh) | 一种新型棘白菌素类抗真菌药物组合物及其制备方法 | |
CN111494311B (zh) | 一种盐酸多巴胺注射液及其制备方法 | |
CN103784397B (zh) | 葛根素磷酸酯钠注射液及其制备方法 | |
CN103054883B (zh) | 一种含有果糖二磷酸钠化合物的药物组合物 | |
CN104856946B (zh) | 一种***磷酸钠注射液及其制备工艺 | |
CN102145162B (zh) | 一种治疗早产药物的注射剂 | |
CN113456654B (zh) | 一种稳定的药物组合物 | |
CN109758423A (zh) | 使用维生素k1脂肪乳注射液治疗凝血功能障碍的方法 | |
CN101836997B (zh) | 一种甘油与果糖组合物的制备方法 | |
CN103202805B (zh) | 一种含有长春西汀的注射用药物组合物及其制备方法 | |
CN102441160B (zh) | 一种胸腺肽α1药物组合物及其制备方法 | |
CN106727611A (zh) | 用于预防和治疗血管性疾病的化合物及其制剂 | |
Araie et al. | Intraocular irrigating solutions and permeability of the blood-aqueous barrier | |
CN100560068C (zh) | 左旋舒必利注射剂的制备方法 | |
KR20120022293A (ko) | 산양산삼 추출물을 함유한 혈관주입용 약제학적 조성물 | |
CN109806226A (zh) | 维生素k1脂肪乳注射液的用途 | |
CN104922661A (zh) | 一种含有serelaxin的药物组合物及其制备方法 | |
CN101628022A (zh) | 一种红花滴丸及其制备方法 | |
CN112516125B (zh) | 酪氨酸在制备防治葛根素注射剂诱发的血管内溶血的药物上的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170306 Address after: 518005 Luohu District International Trade Center building, Renmin South Road, Guangdong, Shenzhen, China B11 Patentee after: SHENZHEN XINGYIN PHARMACEUTICAL Co.,Ltd. Address before: 518057 Guangdong city of Shenzhen province Nanshan District high a No. ten Shenzhen biological incubator base No. 2 building 412 room Patentee before: SHENZHEN JYMED TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Puerarin sodium phosphate injection and its preparation method Effective date of registration: 20201203 Granted publication date: 20160120 Pledgee: Luohu sub branch of Shenzhen Rural Commercial Bank Co.,Ltd. Pledgor: SHENZHEN XINGYIN PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980008795 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210513 Granted publication date: 20160120 Pledgee: Luohu sub branch of Shenzhen Rural Commercial Bank Co.,Ltd. Pledgor: SHENZHEN XINGYIN PHARMACEUTICAL Co.,Ltd. Registration number: Y2020980008795 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Puerarin sodium phosphate injection and its preparation method Effective date of registration: 20210713 Granted publication date: 20160120 Pledgee: Luohu sub branch of Shenzhen Rural Commercial Bank Co.,Ltd. Pledgor: SHENZHEN XINGYIN PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980006080 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230920 Granted publication date: 20160120 Pledgee: Luohu sub branch of Shenzhen Rural Commercial Bank Co.,Ltd. Pledgor: SHENZHEN XINGYIN PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980006080 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Puerarin phosphate sodium injection and its preparation method Effective date of registration: 20230925 Granted publication date: 20160120 Pledgee: Luohu sub branch of Shenzhen Rural Commercial Bank Co.,Ltd. Pledgor: SHENZHEN XINGYIN PHARMACEUTICAL Co.,Ltd. Registration number: Y2023980058573 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |